Fate Therapeutics loses summary judgment in patent case against Shoreline; plans appeal

FATE THERAPEUTICS INC

Court granted Shoreline's summary judgment of non-infringement on Whitehead Patents covering iPSC technology.
Fate strongly disagrees with ruling and will consider appeal; validity and enforceability of patents unaffected.
State case for breach of contract and fraud against Shoreline ongoing; trial set for January 2024.
Shoreline argued it purchases iPSC lines from third parties, not directly infringing Fate's patents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.